You searched for "Gene therapy"
Type 3 macular neovascularisation (MNV) due to age-related macular degeneration
3 October 2024
| Sofia Rokerya
|
EYE - Vitreo-Retinal
This paper systematically reviews and summarises the current knowledge on type 3 neovascularisation due to age-related macular degeneration which is defined as neovascularisation originating from the retinal deep capillary plexus that grows towards the outer retina often penetrating the level...
Music and song inspire Freya to start speaking
30 January 2024
|
More Than Meets The Eye, Charity, Sight Scotland, campaign, sight loss, Royal Blind School
Freya Reily, who is six years old from Tranent in East Lothian, is more than meets the eye. Freya, who was born very prematurely and has severe vision impairment, has been inspired by music and song to start speaking, something that her parents did not think was possible just a few short months ago.
Uveal melanoma
3 August 2023
| Mertcan Sevgi, Timothy Beckman, Paul Cauchi, Julie Connolly, Vikas Chadha
|
EYE - Pathology, EYE - Oncology, EYE - Imaging
Uveal melanoma is the most common primary intraocular tumour. However, they are still rare, with an incidence of 2-8 per million [1]. The presence of a choroidal naevus is a risk factor for uveal melanoma [1]. Patients with choroidal lesions...
Retinoblastoma risk factors for recurrence
7 April 2021
| Fiona Rowe (Prof)
|
Paediatric Ophthalmology / Strabismus
This study evaluates risk factors for local tumour recurrence of main solid tumour, subretinal seed, vitreous seed and new tumour formation in eyes with retinoblastoma (RB) management with primary chemotherapy over 20 years of follow-up. The study included 960 eyes...
Results of changed treatment for retinoblastoma
1 February 2015
| Fiona Rowe (Prof)
|
Paediatric Ophthalmology / Strabismus
Systemic chemotherapy was adopted in Kobe in 1996. In this study the authors analyse the clinical manifestations and results of treatment for patients with retinoblastoma since then. This review is of 43 eyes of 34 patients. Those with follow-up to...
Ten-year experience with intracameral chemotherapy for aqueous seeding in retinoblastoma: long-term efficacy, safety and toxicity
This is a retrospective review of all consecutive patients with primary (n=4) or secondary non-iatrogenic (n=16) aqueous seeding (AS) treated by intracameral chemotherapy (ICC) in Lausanne between 2011 and 2020 with a minimum follow-up of one year. Aqueous seeding control...6.6.2020 – a celebration of international partnerships
5 October 2020
| Allen Foster (Prof), Josiah Onyango, John Nkurikiye, Mike Burdon, Melanie Corbett, Marcia Zondervan
|
EYE - Cataract, EYE - Cornea, EYE - Glaucoma, EYE - Imaging, EYE - Neuro-ophthalmology, EYE - Oculoplastic, EYE - Oncology, EYE - Orbit, EYE - Paediatrics, EYE - Pathology, EYE - Refractive, EYE - Strabismus, EYE - Vitreo-Retinal, EYE - General
The date 6.6.2020 was selected as a significant milestone for celebrating the achievements of the VISION LINKS Programme as part of the global ‘VISION 2020: The Right to Sight’ initiative [1]. This virtual full-day seminar included LINK partners in the...
Initiatives in macular service provision
1 December 2015
| Rod McNeil
|
EYE - Vitreo-Retinal
A report from Monitor in October 2015 identifies good practices that will realise most of the potential productivity gain in elective care available to NHS hospitals. These include: stratifying patients by risk and creating low-complexity pathways for lower-risk patients (tailoring...
Choosing a subspecialty
1 October 2019
| Gwyn Samuel Williams
|
EYE - Cataract, EYE - Cornea, EYE - Glaucoma, EYE - Imaging, EYE - Neuro-ophthalmology, EYE - Oculoplastic, EYE - Oncology, EYE - Orbit, EYE - Paediatrics, EYE - Pathology, EYE - Refractive, EYE - Strabismus, EYE - Vitreo-Retinal, EYE - General
It is quite worrying how many registrars reach the final years of training without choosing a subspecialty. Sometimes this is because they love everything and cannot countenance giving any of it up, but more commonly this is due to various...
Protecting retinal ganglion cells
1 August 2017
| Sofia Rokerya
|
EYE - Glaucoma
Glaucoma is considered to be a heterogeneous group of conditions giving retinal ganglion cells (RGC) damage. Lowering intraocular pressure (IOP) reduces the risk of progressive RGC loss in glaucoma. Regeneration of the optic nerve has been shown to restore some...
Orbital cellulitis in Scotland: current incidents, aetiology, management and outcomes
This is a one year prospective study using the Scottish ophthalmic surveillance unit reporting system amongst Scottish ophthalmologists. Only patients residing within Scotland with a new diagnosis of orbital cellulitis between November 2011 and October 2012 were including in this...
Undetected retinoblastoma management following vitrectomy
5 October 2020
| Annes Ahmeidat
|
Paediatric Ophthalmology / Strabismus
This retrospective study from a single-centre referral university hospital in Germany analysed data collected between 1991-2019 to comment on management and complications of undetected retinoblastoma eyes following vitrectomy. The 10 patients included had a mean age of 36.1 months (range...
